Showing 4081-4090 of 9301 results for "".
- Dr. Roy Geronemus Awarded the Inaugural Vic Narurkar, MD Innovations in Aesthetic Dermatology Lectureship Awardhttps://practicaldermatology.com/news/dr-roy-geronemus-awarded-the-vic-narurkar-md-innovations-in-aesthetic-dermatology-lectureship-award/2460210/Roy Geronemus, MD of Laser & Skin Surgery Center of New York received, The American Society for Dermatologic Surgery inaugural Vic Narurkar, M.D., Innovations in Aesthetic Dermatology Lectureship Award Dr. Geronemus received the award at the 2019 ASDS annual meeting in Chicago. He delivered the le…
- New AAD/NPF Guidelines Address Care for Pediatric Psoriasishttps://practicaldermatology.com/news/new-aadnpf-guidelines-address-care-for-pediatric-psoriasis/2460204/New guidelines from the American Academy of Dermatology and the National Psoriasis Foundation offer counsel on how to best manage psoriasis and its extracutaneous manifestations in children and adolescents. The 2019 guidelines of care for the management and treatment of psoriasis in pediatric pati…
- Good Oral Health and Diet May Improve Psoriasishttps://practicaldermatology.com/news/good-oral-health-and-diet-may-improve-psoriasis/2460201/Dental health and diet may have an impact on the development and severity of psoriasis, according to researchers from The Ohio State University Wexner Medical Center in Columbus. The study found psoriasis patients who rated their gum health as poor or very poor exhibited significantly more severe …
- UCB Presents New Data for Cimzia, Investigational Bimekizumabhttps://practicaldermatology.com/news/ucb-presents-new-data-for-cimzia-investigational-bimekizumab/2460193/Data on the use of UCB’s Cimzia (certolizumab pegol), in psoriasis and psoriatic arthritis (PsA) as well as Phase 2 data for the company’s investigational molecule bimekizumab have been presented at the 28thEuropean Academy of Dermatology and Venereology congress (EADV) in Madrid. Cimzia is a Fc-fr…
- Foamix Update: Nine Trials in Five Postershttps://practicaldermatology.com/news/foamix-update-nine-trials-in-five-posters/2460192/Results from nine clinical trials of Foamix Pharmaceutical investigational products will be presented in five posters at the 39th Annual Fall Clinical Dermatology Conferencein Las Vegas. Findings relate FMX101 for the treatment of moderate-to-severe acne and FMX103 for the treatment of moderate-to-…
- Lilly: New Data for Treatment of Complex Dermatological Conditions at EADV, Maui Derm NP+PAhttps://practicaldermatology.com/news/lilly-new-data-for-treatment-of-complex-dermatological-conditions-at-eadv-maui-derm-nppa/2460188/New data for Eli Lilly and Company’s Taltz® (ixekizumab), Olumiant® (baricitinib) and mirikizumab have been presented at the 28th annual European Academy of Dermatology and Venereology (EADV) Congress in Madrid. The company says the research highlighted at this year's meeting reinforces Lilly's com…
- Verrica Pharmaceuticals: Positive Data for VP-102 for Molluscum Contagiosum, Wartshttps://practicaldermatology.com/news/verrica-pharmaceuticals-positive-data-for-vp-102-for-molluscum-contagiosum-warts/2460187/Positive data for VP-102 (cantharidin 0.7% Topical Solution) from Verrica Pharmaceuticals, Inc. are being presented in poster form at the Annual Fall Clinical Dermatology Conference in Las Vegas. Company’s lead product candidate is being developed for the treatment of molluscum contagiosum and com…
- Psoriasis Linked to Developing and Dying from Cancerhttps://practicaldermatology.com/news/psoriasis-linked-to-developing-and-dying-from-cancer/2460185/Psoriasis may increase the risk for certain cancers, according to a review of 58 studies published in JAMA Dermatology. Moreover, the risk of dying from certain site-specific cancers was elevated in those with severe psoriasis. Specifically, severe psoriasis and all severities of psoriasis were …
- EPI Health Acquires Worldwide Rights to Rhofade from Aclarishttps://practicaldermatology.com/news/epi-health-acquires-worldwide-rights-to-rhofade-from-aclaris/2460180/EPI Health, LLC, has acquired Rhofade (oxymetazoline hydrochloride) cream, 1% and related intellectual property assets from Aclaris Therapeutics, Inc. Rhofade is indicated for the topical treatment of persistent facial erythema associated with rosacea in adults. “We are excited about the acquisiti…
- EADV News: Psoriasis Largely Undertreated, Travels with Anxietyhttps://practicaldermatology.com/news/eadv-news-psoriasis-largely-undertreated-travels-with-anxiety/2460175/Many psoriasis patients remain un- or undertreated, with an average diagnosis time of five years, according to research presented at the 28th European Dermato-Venereology Society Congress in Madrid. In the study of 650 psoriasis patients in Germany, more than half of patients (56 percent) with mor…